ACRS Earnings & Financial Statements
Aclaris Therapeutics, Inc.
$3.38
-$0.09(-2.59%)
41
Overall
60
Value
27
Tech
36
Quality
Market Cap
$497.53M
Volume
2.59M
52W Range
$1.74 - $6.60
Target Price
$10.18
ACRS earnings and financial statements: Aclaris Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ACRS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $7.83M | $18.72M | $31.25M | $29.75M | $6.76M |
| Cost of revenue | $7.28M | $2.79M | $3.42M | $11.96M | $4.71M |
| Operating income | -$76.38M | -$141.93M | -$97.36M | -$89.85M | -$89.72M |
| EBITDA | -$64.47M | -$131.26M | -$87.98M | -$84.36M | -$64.46M |
| Net income | -$64.92M | -$132.06M | -$88.48M | -$86.91M | -$90.86M |
| EPS (diluted) | $-0.53 | $-1.71 | $-1.27 | $-1.33 | $-1.60 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $160.46M | $220.33M | $197.41M | $254.60M | $251.21M |
| Total liabilities | $57.38M | $64.77M | $40.23M | $56.98M | $53.87M |
| Shareholders’ equity | $103.08M | $155.55M | $157.18M | $197.62M | $197.34M |
| Cash and equivalents | $19.96M | $24.57M | $39.88M | $45.28M | $27.35M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$47.11M | -$20.07M | -$78.33M | -$67.57M | -$52.13M |
| Capital expenditure | -$111.0K | -$35.93M | -$1.31M | -$605.0K | -$308.0K |
| Free cash flow | -$47.22M | -$56.01M | -$79.63M | -$68.17M | -$52.44M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ACRS | $3.38 | -2.6% | 2.59M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Aclaris Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW